Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas

NCT03113500 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03113500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03113500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 25, 2017
Completion date
April 25, 2027
Enrollment
48 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adult t-cell leukemia/lymphoma, anaplastic large cell lymphoma, alk-negative, anaplastic large cell lymphoma, alk-positive, angioimmunoblastic t-cell lymphoma, ann arbor stage ii noncutaneous anaplastic large cell lymphoma, ann arbor stage iii noncutaneous anaplastic large cell lymphoma, ann arbor stage iv noncutaneous anaplastic large cell lymphoma, enteropathy-associated t-cell lymphoma, hepatosplenic t-cell lymphoma, mature t-cell and nk-cell non-hodgkin lymphoma, peripheral t-cell lymphoma, not otherwise specified